Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful diligently but unsuccessfully to create a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past few shares. My first CytoDyn post, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set away the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire employment interview that I came away with a bad impression of the company.

Irony of irony, the poor impression of mine of the business has grown steadily, though the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this know-how and connected intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) along with the first brand new drug application approval ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and many therapies, it’s this individual therapies in addition to a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications and multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That is a question I have been asking myself through the very start of my interest in this business. Judging by the multiples of thousands of various responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or possibly some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *